Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Head and Neck Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 4Ovarian Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Anus Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Small Cell Lung Carcinoma 1Skin Neoplasms 1Select Advanced Solid Tumors 1SCLC, Extensive Stage 1SCLC 1Retinoblastoma 1Retinal Neoplasms 1Recurrence 1Radiation Therapy 1Prostatic Neoplasms 1

Interventions

tebentafusp 1pembrolizumab 1Drug Therapy 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Select Advanced Solid Tumors × Drug Therapy × Clear all
NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡